Please provide your email address to receive an email when new articles are posted on . Fewer people with diabetes filled glucagon prescriptions in 2021 compared with 2011, though increases were seen ...

Opko Health and Entera Bio have formalized their partnership as the biotechs prepare to take the first orally administered dual agonist glucagonlike-peptide 1 (GLP-1)/glucagon peptide into the clinic.

Severe hypoglycemia (low blood sugar) can cause people with diabetes to have seizures or lose consciousness, which can make it impossible to treat low blood sugar by eating or drinking something ...

In a recent article published in Science, researchers reviewed clinical studies on the advantages of glucagon-like peptide-1 (GLP-1) medicines beyond glycemic and weight control. GLP-1 medications, ...

Xeris Pharmaceuticals has teamed up with the American Diabetes Association (ADA) to raise awareness of the importance of prescribing glucagon, positioning the partners to address a fundamental barrier ...

While wholesale costs for glucagon skyrocketed over the past decade, out-of-pocket costs haven't increased by much, researchers reported. The cost of unmixed glucagon increased 192% from 2010 to 2020 ...

Glucagon-like peptide-1 receptor agonists and incidence of obesity-related cancer in adults with diabetes: A target-trial emulation study. This is an ASCO Meeting Abstract from the 2025 ASCO Annual ...

Glucagon is a peptide hormone secreted primarily from the alpha cells of the pancreatic islets of Langerhans. Minor amounts are also produced in the L cells of the intestine and certain neurons of the ...